Cystic Fibrosis Transmembrane Behavioral Regulator Modulator, Pharmaceutical Compositions, Treatment Methods, and Process for Producing the Modulator

Abstract

Compounds of formula (I) are described: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the preceding compounds, and metabolites of any of the preceding compounds. Pharmaceutical compositions comprising these compounds, methods for treating cystic fibrosis using these compounds, and methods for preparing them are also described. Solid forms of compound 1 and its salts and solvates are further described.